Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Phase III Trial of TAP-144-SR (3M) in SBMA (JASMITT)
jRCT1091220111Phase 3Completed
- Sponsor
- K-Pharma
- Start
- Feb 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in spinal and bulbar muscular atrophy (SBMA), sponsored by K-Pharma. Primary endpoint: Pharyngeal barium residue in videofluorography. Started Feb 2013; status: completed.
02
Drugs
leuprolide
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on jRCT1091220111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220111.